SK bioscience Statistics

Total Valuation

SK bioscience has a market cap or net worth of KRW 3.06 trillion. The enterprise value is 2.52 trillion.

Market Cap	3.06T
Enterprise Value	2.52T

Important Dates

The next estimated earnings date is Monday, April 28, 2025.

Earnings Date	Apr 28, 2025
Ex-Dividend Date	n/a

Share Statistics

SK bioscience has 78.35 million shares outstanding. The number of shares has increased by 0.24% in one year.

Current Share Class	n/a
Shares Outstanding	78.35M
Shares Change (YoY)	+0.24%
Shares Change (QoQ)	+1.78%
Owned by Insiders (%)	0.11%
Owned by Institutions (%)	3.81%
Float	25.81M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	11.45
PB Ratio	1.51
P/TBV Ratio	1.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-46.73
EV / Sales	9.41
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-8.61

Financial Position

The company has a current ratio of 5.08, with a Debt / Equity ratio of 0.19.

Current Ratio	5.08
Quick Ratio	4.34
Debt / Equity	0.19
Debt / EBITDA	n/a
Debt / FCF	-1.34
Interest Coverage	-37.57

Financial Efficiency

Return on equity (ROE) is -2.69% and return on invested capital (ROIC) is -4.18%.

Return on Equity (ROE)	-2.69%
Return on Assets (ROA)	-3.68%
Return on Invested Capital (ROIC)	-4.18%
Return on Capital Employed (ROCE)	-5.47%
Revenue Per Employee	271.90M
Profits Per Employee	-54.76M
Employee Count	984
Asset Turnover	0.11
Inventory Turnover	1.63

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -31.04% in the last 52 weeks. The beta is 1.18, so SK bioscience's price volatility has been higher than the market average.

Beta (5Y)	1.18
52-Week Price Change	-31.04%
50-Day Moving Average	42,615.00
200-Day Moving Average	50,250.00
Relative Strength Index (RSI)	44.24
Average Volume (20 Days)	96,350

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK bioscience had revenue of KRW 267.55 billion and -53.88 billion in losses. Loss per share was -698.00.

Revenue	267.55B
Gross Profit	30.08B
Operating Income	-138.43B
Pretax Income	-89.11B
Net Income	-53.88B
EBITDA	-89.21B
EBIT	-138.43B
Loss Per Share	-698.00

Full Income Statement

Balance Sheet

The company has 1.16 trillion in cash and 392.81 billion in debt, giving a net cash position of 765.29 billion or 9,767.98 per share.

Cash & Cash Equivalents	1.16T
Total Debt	392.81B
Net Cash	765.29B
Net Cash Per Share	9,767.98
Equity (Book Value)	2.02T
Book Value Per Share	23,007.37
Working Capital	1.27T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -128.02 billion and capital expenditures -164.41 billion, giving a free cash flow of -292.43 billion.

Operating Cash Flow	-128.02B
Capital Expenditures	-164.41B
Free Cash Flow	-292.43B
FCF Per Share	-3,732.53

Full Cash Flow Statement

Margins

Gross margin is 11.24%, with operating and profit margins of -51.74% and -20.14%.

Gross Margin	11.24%
Operating Margin	-51.74%
Pretax Margin	-33.31%
Profit Margin	-20.14%
EBITDA Margin	-33.34%
EBIT Margin	-51.74%
FCF Margin	n/a

Dividends & Yields

SK bioscience does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.24%
Shareholder Yield	-0.24%
Earnings Yield	-1.76%
FCF Yield	-9.55%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK bioscience has an Altman Z-Score of 3.91.

Altman Z-Score	3.91
Piotroski F-Score	n/a